Skip to main content

Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma

Conference Correspondent - Conference Highlights ASH

In this preclinical research effort, Zhang and colleagues showed that various subunits of immunoproteasome are highly expressed in mantle-cell lymphoma (MCL) cells. In particular, expression of specific immunoproteasome subunits is correlated with the activity of carfilzomib––a novel second-generation proteasome inhibitor––in MCL cells. Both primary and established MCL cells with high expression of immunoproteasome subunits were more responsive to carfilzomib, even at low doses. Conversely, MCL cells with low or no expression of immunoproteasome subunits were highly resistant to carfilzomib. These data suggest that the immunoproteasome could serve as a biomarker for identifying patients who will benefit from carfilzomib therapy.

Because Bruton’s tyrosine kinase (BTK) is essential for B-cell lymphoma growth and survival, Zhang and colleagues combined ibrutinib, a novel BTK inhibitor, with carfilzomib to treat carfilzomib- resistant MCL cells. In the preclinical cell model, ibrutinib sensitized these MCL cells, overcoming carfilzomib resistance.

The study authors concluded the BTK inhibitor ibrutinib appears to overcome carfilzomib resistance in MCL cells, suggesting that ibrutinib offers a unique therapeutic approach. Based on these data, clinical trials of ibrutinib combined with carfilzomib in patients with relapsed or refractory MCL are warranted.


Zhang L, Ou Z, Wang J, et al. Ibrutinib overcomes carfilzomib resistance in immunoproteasome-deficient mantle cell lymphoma. Blood. 2013;122. Abstract 3074.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on February 25, 2020 in Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Videos published on January 5, 2016 in Conference Highlights ASH
Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Last modified: August 30, 2021